Thrombin Peptide Derivatives Inhibit Apoptosis via NPAR Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic and progressive diseases such as scleroderma, macular degeneration, diabetic retinopathy, Huntington's disease, Parkinson's disease, closed head trauma, glaucoma, and allograft vasculopathy are inadequate in reversing, slowing, or arresting disease progression, leading to significant quality of life impairments for patients.
Innovation Solution
Administration of thrombin peptide derivatives that act as agonists for non-proteolytically activated receptors (NPAR), which can inhibit apoptosis and exert therapeutic effects by stimulating cellular signals independent of thrombin's proteolytic activity, thereby treating the mentioned diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for degenerative diseases, then disease progression is managed, but the treatments are inadequate in reversing, slowing, or arresting progression
Solution Approach 1:
The patent applies parameter changes by using thrombin peptide derivatives with specific amino acid sequences (12-23 residues) that mimic thrombin's structure but activate NPAR without proteolytic activity. This structural parameter change enables the peptide to bind to and activate the receptor, triggering intracellular signaling cascades that protect against apoptosis and disease progression, thereby improving treatment effectiveness while addressing the inadequacy of conventional therapies
2Reliability
If thrombin peptide derivatives are administered, then apoptosis is inhibited and disease progression is reduced, but the mechanism must be independent of proteolytic activity
Solution Approach 1:
The patent extracts the receptor-binding and signaling-activation function from thrombin's complete enzymatic activity. By using peptide derivatives that contain only the essential amino acid sequences for NPAR binding (without the full thrombin structure), the invention separates the beneficial signaling function from the proteolytic activity, simplifying the mechanism while maintaining therapeutic effect
Solution Approach 2:
The thrombin peptide derivatives act as intermediaries that bridge the extracellular environment and intracellular signaling pathways. These peptides bind to NPAR on the cell surface and transmit signals into the cell, activating protective pathways without requiring the complex proteolytic cascade of full thrombin, thus reducing mechanism complexity while preserving therapeutic benefit
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of thrombin peptide derivatives as NPAR agonists can significantly reduce the progression or severity of these diseases, alleviate symptoms, and in some cases, delay the development of these conditions by up to 90%, improving the quality of life for patients.
Implementation Method 1
Agonists of a non-proteolytically activated receptor (NPAR) can be used in methods for treating a disease or disorder in a subject. NPAR agonists may exert their effect by inhibiting apoptosis.
Data Source
AI summary
Agonists of a non-proteolytically activated receptor can be used in methods for treating a disease or disorder in a subject. The methods comprise administering to the subject a therapeutically effective amount of an agonist, wherein the disease or disorder is scleroderma, macular degeneration, diabetic retinopathy, Huntington's disease, Parkinson's disease, closed head trauma, glaucoma, optic neuritis or allograft vasculopathy.